Guggenheim raises Merck stock price target to $170 on cancer drug

Guggenheim raised Merck's price target to $170 from $146 and maintained a Buy rating, estimating approximately $7 billion in probability-adjusted 2035 sales for intismeran autogene following positive Phase 3 melanoma data. The firm also projects roughly $7 billion in 2035 sales potential for sacituzumab tirumotecan, with key detailed trial data expected at ESMO in October. Merck shares have risen 11.2% since the intismeran topline release versus a 0.4% gain for the S&P 500, although Keytruda's future biosimilar and pricing pressure remains a major headwind.

Analysis

MRK’s post-Keytruda valuation debate is shifting from a single-asset patent-cliff discount toward pipeline replacement credibility, but the market should not capitalize distant oncology optionality at full value before durability, safety, manufacturing throughput, and reimbursement are established. The economically relevant variable is not headline addressable market but recurrence-free-survival durability and eventual overall-survival evidence; absent the latter, adjuvant uptake can be meaningful yet remain constrained by payer scrutiny and physician reluctance to treat potentially cured patients. October disclosures are therefore a de-risking catalyst, but commercial contribution is a 2028-30+ issue rather than a near-term EPS bridge.

MRNA has higher equity sensitivity because oncology validation would expand the perceived value of its platform beyond respiratory vaccines, while MRK retains substantially more downside protection from its existing commercial base and capital-return capacity. The asymmetric risk is that investors extrapolate a first successful personalized mRNA oncology program to BNTX, NVAX, and the broader biotech complex despite materially different antigen selection, delivery, trial design, and partner economics. A broad biotech rally would likely reverse quickly if detailed data show only marginal absolute benefit, short follow-up, or a safety/discontinuation burden that undermines real-world adoption.

Sacituzumab tirumotecan is strategically more important to MRK’s medium-term replacement narrative than its current valuation contribution suggests: successful global translation of China-generated data would validate a lower-cost external-innovation channel and improve confidence in dealmaking discipline. Conversely, any geographic efficacy gap, interstitial-lung-disease signal, or regulatory request for additional global evidence would reintroduce a 2028-30 revenue-gap narrative and compress MRK’s premium versus large-cap pharma peers. The consensus risk is treating multiple pipeline readouts as independent; a weak ESMO package would simultaneously impair both the growth-duration narrative and management’s credibility on business-development execution.

Key Decisions for Investors

• Maintain MRK as a core defensive long only on a 6-18 month horizon; add on post-ESMO weakness if detailed efficacy supports a clinically meaningful absolute benefit without new safety liabilities. Thesis fails if management cannot maintain post-Keytruda earnings-growth guidance or if global regulatory timelines slip materially.
• Express higher-beta oncology-platform upside through a defined-risk MRNA call spread expiring after the October data event rather than chasing common stock after its repricing. Size modestly: attractive only if implied volatility does not already price a large post-event move; exit if durability data fail to improve confidence in broad platform applicability.
• Avoid using BNTX or NVAX as direct sympathy longs. They may initially benefit from category beta, but neither has demonstrated that the MRK/MRNA development, manufacturing, and commercialization model transfers to its own pipeline; fade outsized peer moves lacking asset-specific catalysts.
• Watch MRK versus large-cap pharma peers over the next 1-3 months: sustained relative strength after detailed data would support a multiple re-rating, while underperformance despite positive data signals the market views pipeline value as too remote to offset nearer-term loss-of-exclusivity exposure.